In addition, several studies are recruiting patients to test this compound in different clinical settings, including gastric, urothelial or biliary tract HER2+ cancer, and HER2 low breast cancer, among others (NCT04924699, NCT04941339, NCT04839510, NCT04837508, NCT04742153, and NCT04492488). The gene discussed is ERBB2; the disease is breast carcinoma.